After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus ...

This integration with Sage 200 is another step forward in delivering smarter, more efficient debtor management solutions that help businesses thrive.” Discover how Chaser can transform your ...

Sage 200 Evolution customers heard from Sage guest speakers, including Gerhard Hartman, Sage Regional Vice-President, Medium Segment, Africa and Middle East, and Jordaan Burger, ...

In trading on Monday, shares of Sage Therapeutics Inc (Symbol: SAGE) crossed below their 200 day moving average of $43.85, changing hands as low as $43.74 per share. Sage Therapeutics Inc shares ...

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that ...

These are companies that are too large even for Sage's 200 products, targeted to companies of about 200 employees. Competition is increasing in this segment. During the call, ...